For the first time, we combined a quantitative synthesis of data from human and non-human sources of evidence regarding the efficacy, tolerability, and mechanism of action of TAAR1 agonists in treating psychosis, which goes beyond previous reviews6,9,70–73. The gene discussed is TAAR1; the disease is psychotic disorder.